Hetero Labs Limited Raltegravir Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Raltegravir Export Records India — #1 Exporter, 19 Shipments, $950.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Raltegravir

India Pharmaceutical Trade Intelligence

$6.4M29 Suppliers27 CountriesHS 30049099

ExportsIndia → GUATEMALA32.6%India → PERU30.1%

ImportsUNITED STATES → India$73.2K GERMANY → India$58.2K

#1 Supplier: HETERO LABS

Hetero Labs Limited — Raltegravir Exporter #1 | $950.0K Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Raltegravir Exporter Profile

Indian Pharmaceutical Exporter · #1 for Raltegravir · $950.0K export value · DGFT Verified

Hetero Labs Limited is the #1 Indian exporter of Raltegravir with $950.0K in export value and 19 verified shipments. Hetero Labs Limited holds a 16.8% market share in Raltegravir exports across 6 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Raltegravir Export Profile: Buyers & Destinations

Hetero Labs Limited Raltegravir export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Raltegravir?

Country	Value	Shipments	Share
PANAMA	$250.0K	5	33.2%
PERU	$200.0K	4	26.6%
NEPAL	$126.9K	3	16.8%
RWANDA	$66.2K	4	8.8%

Who Are the Top Buyers of Raltegravir from Hetero Labs Limited?

Buyer	Country	Value	Orders
TO THE ORDER OF	PANAMA	$326.4K	10
TO EVEREST BANK LIMITED,	NEPAL	$126.9K	3
TO THE ORDER OF , . , . , . , . , .	PANAMA	$100.0K	2
CENTRO NACIONAL DE ABASTECIMIENTO	PERU	$50.0K	1
M S TO THE ORDER	PANAMA	$50.0K	1
SEVEN PHARMA PANAMA S.A.	PANAMA	$50.0K	1
TO THE ORDER OF.	LIBYA	$50.0K	1

Hetero Labs Limited supplies Raltegravir to 7 buyers globally. The largest buyer is TO THE ORDER OF (PANAMA), followed by TO EVEREST BANK LIMITED, (NEPAL) and TO THE ORDER OF , . , . , . , . , . (PANAMA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Raltegravir Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
RALTEGRAVIR POTASSIUM 400 MG TABS (QTY:	$100.0K	2
RALTEGRAVIR 400MG TAB (SPA RALTEGRAVIR P	$50.0K	1
RALTEGRAVIR POTASSIUM 400 MG TABS (1748	$50.0K	1
RALTAVIR 400 MG RALTEGRAVIR POTASSIUM 40	$50.0K	1
RALTEGRAVIR POTASSIUM 400 MG TABS (2082	$50.0K	1
RALTEGRAVIR POTASSIUM 400 MG TABS 2389 PACKS 60'S/PAC	$50.0K	1
RALTEGRAVIR POTASSIUM TABLET	$50.0K	1
TENOFOVIR / LAMIVUDINE / DOLUTEGRAV VIR(300MG / 300 MG 50 / MG) / RALTEGRAVIR VIR 400 MG	$50.0K	1
TENOFOVIR / LAMIVUDINE / DOLUTEGRAVIR (300MG / 300 MG 50 / MG) / RALTEGRAVIR 400MG	$50.0K	1
RALTEGRAVIR POTASSIUM TABLET (RALTAVIR)	$50.0K	1

Hetero Labs Limited exports 16 distinct Raltegravir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RALTEGRAVIR POTASSIUM 400 MG TABS (QTY: with 2 shipments worth $100.0K.

How Does Hetero Labs Limited Compare to Nearest Raltegravir Exporters?

Exporters ranked immediately above and below #1 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	TITAN LABORATORIES PRIVATE LIMITED	$1.1M	21	2	$50.0K
1	HETERO LABS LIMITED ★	$950.0K	19	6	$50.0K
3	S.D.PHARMACEUTICALS	$150.0K	3	1	$50.0K
4	BULL PHARMACHEM	$82.1K	4	1	$20.5K

Hetero Labs Limited ranks #1 among 29 Indian Raltegravir exporters. Average shipment value of $50.0K compared to the market average of $79.1K. The closest competitors by value are TITAN LABORATORIES PRIVATE LIMITED and S.D.PHARMACEUTICALS.

Which Indian Ports Ship Raltegravir Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	42	37.2%
SAHAR AIR	24	21.2%
DELHI AIR	7	6.2%
HYDERABAD ACC (INHYD4)	6	5.3%
AHEMDABAD AIR	6	5.3%
NHAVA SHEVA SEA (INNSA1)	4	3.5%
DELHI AIR CARGO ACC (INDEL4)	3	2.7%
Bombay Air	3	2.7%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Raltegravir Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Raltegravir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 19 individual customs records matching Hetero Labs Limited exporting Raltegravir, covering 16 formulations to 6 countries via 7 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 27+ countries, 39+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Raltegravir

Raltegravir

Hetero Labs Limited — Raltegravir Exporter Profile

Hetero Labs Limited — Raltegravir Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Raltegravir?

Who Are the Top Buyers of Raltegravir from Hetero Labs Limited?

What Is India's Total Raltegravir Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Raltegravir Exports?

How Does Hetero Labs Limited Compare to Other Indian Raltegravir Exporters?

What Raltegravir Formulations Does Hetero Labs Limited Export?

How Does Hetero Labs Limited Compare to Nearest Raltegravir Exporters?

Which Indian Ports Ship Raltegravir Exports?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Raltegravir Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Raltegravir Export Data from Hetero Labs Limited

Raltegravir Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source